SCHEMBL3702148

SCHEMBL3702148

Cc1cc(C)n2nc(NC(=O)CCc3ccccc3)c(-c3cccc(C(F)(F)F)c3)c2n1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 3/20 0.52
KCNQ2 O43526 3/20 0.52
POLB P06746 3/20 0.48
KDM4E B2RXH2 2/20 0.48
NR2E1 Q9Y466 1/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MLYCD O95822 1/20 0.43
LMNA P02545 2/20 0.41
RECQL P46063 1/20 0.41
ADORA2A P29274 1/20 0.41
HPGD P15428 2/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 1/20 0.40
APOBEC3A P31941 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3705325 0.88 KCNQ3 (0.54) KCNQ3KCNQ2POLBKDM4EKMT2A
SCHEMBL3708798 0.84 KCNQ3 (0.56) KCNQ3KCNQ2POLBKDM4EKMT2A
SCHEMBL3703282 0.82 KCNQ3 (0.56) KCNQ3KCNQ2POLBKDM4EKMT2A
SCHEMBL3706800 0.77 KCNQ3 (0.46) KCNQ3KCNQ2POLBKDM4EKMT2A
SCHEMBL3702142 0.75 KCNQ3 (0.76) KCNQ3KCNQ2POLBKDM4EKMT2A
SCHEMBL3695035 0.75 KCNQ3 (0.55) KCNQ3KCNQ2POLBKDM4EKMT2A
SCHEMBL3703612 0.74 KCNQ3 (0.77) KCNQ3KCNQ2POLBKDM4E
SCHEMBL3710474 0.74 HCAR2 (0.47) KCNQ3KCNQ2POLBKMT2AMEN1
SCHEMBL3701966 0.73 KCNQ3 (0.56) KCNQ3KCNQ2POLBKDM4ENR2E1
SCHEMBL3704938 0.72 KCNQ3 (0.74) KCNQ3KCNQ2POLBKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US claimed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO claimed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US claimed
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US disclosed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO disclosed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122888-A1 Potassium Channel Modulators KCNQ1, KCNQ2, KCNJ2 KCNQ3 4/4885KCNQ2 2/4885POLB 4527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.